Search research articles
Contact Us
Filters
Showing results (151-160 of 195) with videos related to
Page
of 20
Sort By:
Journal of Crohn'S & Colitis
|
December 2, 2023
Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource
Christina Kapizioni, Rofaida Desoki, Danielle Lam, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
April 1, 2019
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael, Adam S Cheifetz, Gil Y Melmed, et al.
Cell
|
September 20, 2016
Epithelia Use Butyrophilin-like Molecules to Shape Organ-Specific γδ T Cell Compartments
Rafael Di Marco Barros, Natalie A Roberts, Robin J Dart, et al.
Scandinavian Journal of Gastroenterology
|
October 2, 2018
Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study
Jonathan P Segal, Lawrence Penez, Soad Mohsen Elkady, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 5, 2025
Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment
Remo Panaccione, Marc Ferrante, Iris Dotan, et al.
Annals of Gastroenterology
|
March 5, 2020
Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience
Hajir Ibraheim, Mark A Samaan, Ashish Srinivasan, et al.
Alimentary Pharmacology & Therapeutics
|
June 20, 2022
A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centre
Susanna Meade, Kamal V Patel, Raphael P Luber, et al.
Inflammatory Bowel Diseases
|
October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E Sands, Geert D'Haens, David B Clemow, et al.
Lancet (London, England)
|
June 12, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Bruce E Sands, Peter M Irving, Timothy Hoops, et al.
Gut
|
September 3, 2020
Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel
Richard Hansen, Susanna Meade, R Mark Beattie, et al.
Page
of 20
Search research articles
Search
Showing results (151-160 of 195) with videos related to
Sort By:
Page
of 20
Journal of Crohn'S & Colitis
|
December 2, 2023
Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource
Christina Kapizioni, Rofaida Desoki, Danielle Lam, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
April 1, 2019
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases
Konstantinos Papamichael, Adam S Cheifetz, Gil Y Melmed, et al.
Cell
|
September 20, 2016
Epithelia Use Butyrophilin-like Molecules to Shape Organ-Specific γδ T Cell Compartments
Rafael Di Marco Barros, Natalie A Roberts, Robin J Dart, et al.
Scandinavian Journal of Gastroenterology
|
October 2, 2018
Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study
Jonathan P Segal, Lawrence Penez, Soad Mohsen Elkady, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
February 5, 2025
Extended Risankizumab Treatment in Patients With Crohn's Disease Who Did Not Achieve Clinical Response to Induction Treatment
Remo Panaccione, Marc Ferrante, Iris Dotan, et al.
Annals of Gastroenterology
|
March 5, 2020
Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience
Hajir Ibraheim, Mark A Samaan, Ashish Srinivasan, et al.
Alimentary Pharmacology & Therapeutics
|
June 20, 2022
A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disease in a UK tertiary IBD centre
Susanna Meade, Kamal V Patel, Raphael P Luber, et al.
Inflammatory Bowel Diseases
|
October 24, 2024
Three-Year Efficacy and Safety of Mirikizumab Following 152 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study
Bruce E Sands, Geert D'Haens, David B Clemow, et al.
Lancet (London, England)
|
June 12, 2022
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
Bruce E Sands, Peter M Irving, Timothy Hoops, et al.
Gut
|
September 3, 2020
Adaptations to the current ECCO/ESPGHAN guidelines on the management of paediatric acute severe colitis in the context of the COVID-19 pandemic: a RAND appropriateness panel
Richard Hansen, Susanna Meade, R Mark Beattie, et al.
Page
of 20